Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Hans-Juergen Pfannkuche"'
Autor:
Hans-Ulrich Gremlich, Vicente Martínez, Rainer Kneuer, Willy Kinzy, Eckhard Weber, Hans-Juergen Pfannkuche, Markus Rudin
Publikováno v:
Molecular Imaging, Vol 3 (2004)
Noninvasive near-infrared fluorescence reflectance imaging (FRI) is an in vivo technique to assess physiological and molecular processes in the intact organism. Here we describe a method to assess gastric emptying in mice. TentaGel™ beads with cova
Externí odkaz:
https://doaj.org/article/9599b5637d614684b75fa9494ce21027
Autor:
Hans-Juergen Pfannkuche, René de Vries, Antoon J. van den Bogaerdt, Alexander H. J. Danser, Kayi Y. Chan, Antoinette MaassenVanDenBrink, Frank P.J. Leijten
Publikováno v:
European Journal of Pharmacology, 619(1-3), 61-67. Elsevier
Tegaserod, a 5-HT4 receptor agonist, has been used to treat idiopathic constipation and constipation-predominant irritable bowel disease. It has recently been suggested that tegaserod has an affinity for 5-HT1B receptors, which mediate vasoconstricti
Autor:
Henri Mattes, Hans-Juergen Pfannkuche
Publikováno v:
Current Medicinal Chemistry-Central Nervous System Agents. 3:27-36
Autor:
Henri Mattes, Hans-Juergen Pfannkuche
Publikováno v:
Current Medicinal Chemistry-Central Nervous System Agents. 3:37-42
Autor:
Joerg Haier, Robert Mader, Grazyna Wieczorek, Moriko Ito, Hans-Juergen Pfannkuche, Thomas Kocher
Publikováno v:
European journal of gastroenterologyhepatology. 18(9)
BACKGROUND: The serotonin type 4 (5-HT4) receptor has been associated with functions of the gastrointestinal tract such as modulation of the peristaltic reflex, smooth muscle tone, intestinal secretion and visceral sensitivity. The activation of peri
Autor:
Eslie Dennis, Hans-Juergen Pfannkuche
Publikováno v:
Pharmacotherapy. 24(11)
Autor:
Hans-Juergen Pfannkuche, David L. Earnest, Eckhard Weber, Verena Walter, Bryan McDowell, Charles Hall
Publikováno v:
American Journal of Gastroenterology. 104:S172-S173
Publikováno v:
Gastroenterology. 124:A674-A675
Autor:
James A. McRoberts, Hans-Juergen Pfannkuche, Helena S. Ennes, Gareth A. Hicks, Emeran A. Mayer
Publikováno v:
Gastroenterology. 134:A-709
Publikováno v:
Lipids in Health and Disease. 5:15
Background Tegaserod is effective in treating IBS patients with constipation, and does not alter gallbladder motility in healthy individuals or in patients with IBS. However, it is not known if tegaserod affects the biliary tract in gallstone disease